pubmed-article:10543728 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:10543728 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
pubmed-article:10543728 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
pubmed-article:10543728 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
pubmed-article:10543728 | lifeskim:mentions | umls-concept:C0013935 | lld:lifeskim |
pubmed-article:10543728 | lifeskim:mentions | umls-concept:C0085828 | lld:lifeskim |
pubmed-article:10543728 | lifeskim:mentions | umls-concept:C0016030 | lld:lifeskim |
pubmed-article:10543728 | lifeskim:mentions | umls-concept:C1510411 | lld:lifeskim |
pubmed-article:10543728 | lifeskim:mentions | umls-concept:C1709313 | lld:lifeskim |
pubmed-article:10543728 | lifeskim:mentions | umls-concept:C1148673 | lld:lifeskim |
pubmed-article:10543728 | lifeskim:mentions | umls-concept:C0486616 | lld:lifeskim |
pubmed-article:10543728 | lifeskim:mentions | umls-concept:C2266866 | lld:lifeskim |
pubmed-article:10543728 | lifeskim:mentions | umls-concept:C0205349 | lld:lifeskim |
pubmed-article:10543728 | lifeskim:mentions | umls-concept:C1880022 | lld:lifeskim |
pubmed-article:10543728 | lifeskim:mentions | umls-concept:C0596448 | lld:lifeskim |
pubmed-article:10543728 | pubmed:issue | 1 | lld:pubmed |
pubmed-article:10543728 | pubmed:dateCreated | 1999-11-22 | lld:pubmed |
pubmed-article:10543728 | pubmed:abstractText | Transcription factors of the AP-1/ATF family, including c-Fos, c-Jun, and ATF-2, play an important role in the regulation of cell proliferation and differentiation, and changes in their levels and/or activities may contribute to oncogenesis. We analyzed the alterations of AP-1/ATF transcription factors upon immortalization and transformation in a panel of cell lines derived from rat embryo fibroblast (REF) cells. The tumorigenic E1A + cHa-ras cells are characterized by high and constitutive DNA binding activities of AP-1, in contrast to nontransformed cells and the E1A cells. The expression of c-fos and c-jun genes was affected differently by the oncogenic transformation. By using antibodies to c-Jun and c-Fos proteins in electrophoretic mobility shift assays (EMSA), we showed that E1A + cHa-ras transformants did not contain c-Fos under any condition of cell cultivation and growth factor stimulation, whereas c-Jun was constitutively upregulated. In the absence of c-fos gene expression, c-Fos protein appears to be replaced by proteins of Fos family (Fra-1) and ATF family (ATF-2 and ATFa). To determine the possible mechanisms of c-fos downregulation in E1A + cHa-ras transformants we have obtained populations of geneticin-resistant clones containing integrated reporter construct -711fos-CAT and its mutants in serum-responsive element (SRE) and cAMP-responsive element (CRE). Data obtained show that the mutations within the SRE lead to a manifold activation of fos-CAT expression. This allows to suggest that c-fos downregulation in E1A + cHa-ras transformants is provided by a negative control mediated through the SRE regulatory region. The profound differences in regulation and composition of transcription factors of the AP-1 family probably play a pivotal role in the transformation of REF cells by E1A and cHa-ras oncogenes. | lld:pubmed |
pubmed-article:10543728 | pubmed:language | eng | lld:pubmed |
pubmed-article:10543728 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10543728 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:10543728 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10543728 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10543728 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10543728 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10543728 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10543728 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10543728 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:10543728 | pubmed:issn | 1052-2166 | lld:pubmed |
pubmed-article:10543728 | pubmed:author | pubmed-author:van der EbA... | lld:pubmed |
pubmed-article:10543728 | pubmed:author | pubmed-author:PospelovV AVA | lld:pubmed |
pubmed-article:10543728 | pubmed:author | pubmed-author:SvetlikovaS... | lld:pubmed |
pubmed-article:10543728 | pubmed:author | pubmed-author:MedvedevA VAV | lld:pubmed |
pubmed-article:10543728 | pubmed:author | pubmed-author:PospelovaT... | lld:pubmed |
pubmed-article:10543728 | pubmed:author | pubmed-author:KukushkinA... | lld:pubmed |
pubmed-article:10543728 | pubmed:author | pubmed-author:DorsmanJ CJC | lld:pubmed |
pubmed-article:10543728 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:10543728 | pubmed:volume | 8 | lld:pubmed |
pubmed-article:10543728 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:10543728 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:10543728 | pubmed:pagination | 19-32 | lld:pubmed |
pubmed-article:10543728 | pubmed:dateRevised | 2009-12-17 | lld:pubmed |
pubmed-article:10543728 | pubmed:meshHeading | pubmed-meshheading:10543728... | lld:pubmed |
pubmed-article:10543728 | pubmed:meshHeading | pubmed-meshheading:10543728... | lld:pubmed |
pubmed-article:10543728 | pubmed:meshHeading | pubmed-meshheading:10543728... | lld:pubmed |
pubmed-article:10543728 | pubmed:meshHeading | pubmed-meshheading:10543728... | lld:pubmed |
pubmed-article:10543728 | pubmed:meshHeading | pubmed-meshheading:10543728... | lld:pubmed |
pubmed-article:10543728 | pubmed:meshHeading | pubmed-meshheading:10543728... | lld:pubmed |
pubmed-article:10543728 | pubmed:meshHeading | pubmed-meshheading:10543728... | lld:pubmed |
pubmed-article:10543728 | pubmed:meshHeading | pubmed-meshheading:10543728... | lld:pubmed |
pubmed-article:10543728 | pubmed:meshHeading | pubmed-meshheading:10543728... | lld:pubmed |
pubmed-article:10543728 | pubmed:meshHeading | pubmed-meshheading:10543728... | lld:pubmed |
pubmed-article:10543728 | pubmed:meshHeading | pubmed-meshheading:10543728... | lld:pubmed |
pubmed-article:10543728 | pubmed:meshHeading | pubmed-meshheading:10543728... | lld:pubmed |
pubmed-article:10543728 | pubmed:meshHeading | pubmed-meshheading:10543728... | lld:pubmed |
pubmed-article:10543728 | pubmed:meshHeading | pubmed-meshheading:10543728... | lld:pubmed |
pubmed-article:10543728 | pubmed:meshHeading | pubmed-meshheading:10543728... | lld:pubmed |
pubmed-article:10543728 | pubmed:meshHeading | pubmed-meshheading:10543728... | lld:pubmed |
pubmed-article:10543728 | pubmed:year | 1999 | lld:pubmed |
pubmed-article:10543728 | pubmed:articleTitle | E1A + cHa-ras transformed rat embryo fibroblast cells are characterized by high and constitutive DNA binding activities of AP-1 dimers with significantly altered composition. | lld:pubmed |
pubmed-article:10543728 | pubmed:affiliation | Institute of Cytology, Russian Academy of Sciences, St-Petersburg. | lld:pubmed |
pubmed-article:10543728 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:10543728 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10543728 | lld:pubmed |